Skip to content
GenoLensGenoLens

PRDM6

Chr 5q23.2

PR/SET domain 6

Aliases:
PRISM, KMT8C
MANE:
ENST00000407847.5

Annotations refreshed 1 month ago.

Predicted protein structure

Clinical relevance (Genomics England PanelApp)

Moderate Evidence (Amber)

  • Paediatric disorders - additional genes

    MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted
  • DDG2P

    MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknown

Disease associations (Open Targets)

  • persistent fetal circulation syndrome

    0.60
  • hypertensive disorder

    0.53
  • neurodegenerative disease

    0.50
  • essential hypertension

    0.49
  • androgenetic alopecia

    0.46
  • aortic aneurysm

    0.42
  • Increased blood pressure

    0.41
  • cardiovascular disorder

    0.40
  • familial patent arterial duct

    0.40
  • aneurysm

    0.37

Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.

Protein function (UniProt)

Putative histone-lysine N-methyltransferase PRDM6

Putative histone methyltransferase that acts as a transcriptional repressor of smooth muscle gene expression. Promotes the transition from differentiated to proliferative smooth muscle by suppressing differentiation and maintaining the proliferative potential of vascular smooth muscle cells. Also plays a role in endothelial cells by inhibiting endothelial cell proliferation, survival and differentiation. It is unclear whether it has histone methyltransferase activity in vivo. According to some authors, it does not act as a histone methyltransferase by itself and represses transcription by recruiting EHMT2/G9a. According to others, it possesses histone methyltransferase activity when associated with other proteins and specifically methylates 'Lys-20' of histone H4 in vitro. 'Lys-20' methylation represents a specific tag for epigenetic transcriptional repression

Curated MONDO disease pages that list PRDM6 among their top associated genes.

Data sources: HGNC (CC BY 4.0), AlphaFold (CC BY 4.0, Jumper et al. Nature 2021), Genomics England PanelApp (CC BY 4.0), ClinGen, Open Targets (CC0), UniProt.

Not for sole clinical decision-making. Always verify against primary sources.